market response surprising, page-10

Well, the news relates to safety in *1* patient and is just the first cohort with the lowest dose...

And I think people forgot that to minimise cross silencing BLT had to screen patients before accepting them into the clinical trial. Meaning you check whether the vector you're inserting won't silent other vital genes in the patient. So you're almost expecting this to be safe

What that also means is that you can't target the entire population... it would be [90%] of the people who wouldn't have a problem with your vector